Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism
Authors:
- A A GibsonAGA A Gibson
- S D BakerSBS D Baker
- A SparreboomASA Sparreboom
- 30 March 2011
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 89 (5) , 693-701
Abstract
The macrolide antiobiotic erythromycin undergoes extensive hepatic metabolism and is commonly used as a probe for cytochrome P450 (CYP) 3A4 activity. By means of a transporter screen, erythromycin wa...Keywords
This publication has 43 references indexed in Scilit:
- Pharmacogenetics of Drug TransportersCurrent Pharmaceutical Design, 2010
- Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and PharmacokineticsJournal of Clinical Oncology, 2009
- Pharmacogenetic Pathway Analysis of Docetaxel EliminationClinical Pharmacology & Therapeutics, 2008
- IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAYDrug Metabolism and Disposition, 2006
- Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortexThe Pharmacogenomics Journal, 2006
- Microsomal prediction ofin vivoclearance and associated interindividual variability of six benzodiazepines in humansXenobiotica, 2005
- Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping ProbesJNCI: Journal of the National Cancer Institute, 2004
- Mdr1Limits CYP3A Metabolism in VivoMolecular Pharmacology, 2000
- Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistanceBiochimica et Biophysica Acta (BBA) - Biomembranes, 1999
- Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-GlycoproteinPharmaceutical Research, 1999